Month: December 2023

As another year draws to a close and a new one begins, thank you for being with us. To end the year, let’s take a look back on December 2023 with the latest edition of the Longevity and DeSci Recap. December 2023 proved a remarkably productive month for longevity research and DeSci innovation. With a...

The holidays are here, and it’s time for a well-earned rest and some festive fun with family and friends! We will take a look at what the Lifespan.io team has been up to recently, so sit back, relax, and enjoy a mince pie while you read the Christmas Editorial! We have been working hard bringing...

The Longevity Investor Network has experienced significant growth and success over the past year. Our mission to connect innovative companies in the longevity sector with forward-thinking investors has seen remarkable achievements, particularly in 2023. Investors On the investor side, we have now over 200 longevity investors that form part of our robust network. Our investor...

According to a new study, the amount of leisure time spent on vigorous physical activity is inversely correlated with Alzheimer’s, but after a certain point, the association is reversed [1]. Outrunning dementia Due to populational aging and medicine’s successes against other age-related diseases, Alzheimer’s disease has become one of the leading causes of mortality in...

Ora Biomedical, a pharmaceutical company that is pioneering novel small molecules to maximize healthy lifespan for humans and companion pets, is excited to announce its strategic collaboration with Lifespan.io as the official charity partner for the Million-Molecule Challenge. The Million-Molecule Challenge, hosted by Ora Biomedical, is a groundbreaking initiative aimed at accelerating research in aging...

In Aging, researchers have published their tests of a compound that counteracts the effects of tumor necrosis factor alpha (TNF-α), an inflammatory factor that promotes arthritis. Current anti-inflammatories aren't enough Rheumatoid arthritis, an autoimmune disorder that causes joint swelling, pain, and disability, is most often treated with anti-inflammatory compounds, such as non-steroidal anti-inflammatory drugs (NSAIDs),...